BioLattice develops a unified platform for biofabrication workflows that simplifies and automates the 3D bioprinting process. The company offers tools for experimental planning, design, and production using various 3D printing technologies, self-described as streamlining the research process.

BioLattice

BioLattice | 321 followers on LinkedIn. Revolutionizing Tissue Repair | We are addressing the need for tissue repair solutions, beginning with cornea. One in 70 patients who need cornea tissue obtain it. Globally 2 million per year suffer from corneal blindness while only 200,000 per year receive vision restoration via cornea transplant.

Materials Scientist

Kyle Thomas Webb

Our CEO (Amelia Zellander, PhD) is looking forward to the Legends Business Gala Brunch hosted by Mom Your Business ( Tanya T Morris ). This glamorous afternoon honors the achievements of our community’s most inspiring entrepreneurs. Tickets are available here: " https://lnkd.in/ewPWk2Gm ".

Our CEO, Amelia Zellander, PhD, appreciated the opportunity to present at Life Sciences Future in King of Prussia, PA yesterday. The conference was a great opportunity to make new connections and catch up with colleagues.

I had the pleasure of presenting at Creating Conscious Collisions in June: https://lnkd.in/eqNvuKTF See this video: https://lnkd.in/eY84gXkp

It was an honor to be invited to "Lunch and Conversation with Mayor Cherelle Parker with Philadelphia Women Leaders", hosted by Morgan, Lewis & Bockius LLP . It was encouraging to hear the Mayor's plans and progress with making Philadelphia safer, cleaner, more prosperous, and more unified. Philadelphia is a special place to me, and I'm hopeful for our future.

Check out our IndieBio website! https://lnkd.in/e8jSDkZT

BioLattice won 2nd place in the Life Sciences category at the Startup302 pitch competition in Delaware!

I am pleased to announce that BioLattice was awarded a National Science Foundation SBIR Phase 1 grant in November 2023. Please see the attached press release.

Thank you to Sarah Huffman at Technical.ly for the November 2023 article on BioLattice. BioLattice's CEO (Amelia Zellander, PhD) won first place at the Enterprise Center's " Most Diverse Tech Hub" pitch competition. Please read the article: https://lnkd.in/e2PNVifr

Thank you to Laura Brzyski at Philadelphia Magazine for the 2021 article on BioLattice. I am catching up on sharing information about the company. Please see the article here: https://lnkd.in/ds74W-e

Metric
Company Name	BioLattice
Symbol
MSH ID	AI:BIOLATTICE
Market	PRIVATE
Sector	Technology
Industry	Biotechnology
Country	US
Stage
Employee Count
Website	biolattice.ai
LinkedIn	biolattice
Founders

Metric
Market Cap
Enterprise Value
Monthly Web Traffic
Web Traffic Growth
Valuation
Raised Capital

Metric
Revenue
Revenue (LTM)
Revenue (NTM)
Gross Profit
EBITDA
Operating Income
Net Income
EPS
Diluted EPS
Revenue 2022
Revenue 2023
Revenue 2024
Revenue 2025
Revenue 2026

Metric
Revenue Growth (LTM)
Revenue Growth (NTM)
Gross Profit Growth (LTM)
EBITDA Growth (LTM)
Net Income Growth (LTM)
14-Day Growth Score
28-Day Growth Score
90-Day Growth Score
365-Day Growth Score

Metric
Gross Profit Margin
Operating Profit Margin
EBITDA Margin
Net Profit Margin
Return on Equity
Return on Assets
Return on Capital Employed

BIOL

AI:BIOLATTICE

BioLattice

Company Overview

Market Metrics

Financial Performance

Growth Metrics

Profitability Ratios

Valuation Multiples

Operational Metrics

Cash Flow Metrics

Balance Sheet Metrics

Efficiency Metrics

Metric
P/E Ratio
P/B Ratio
Revenue Multiple (LTM)
Revenue Multiple (NTM)
EBITDA Multiple (LTM)
EBITDA Multiple (NTM)
Price to Sales Ratio
EV Multiple

Metric
Days Sales Outstanding
Days Payables Outstanding
Days Inventory Outstanding
Operating Cycle
Cash Conversion Cycle
Asset Turnover

Metric
Operating Cash Flow
Free Cash Flow
Cash Flow to Debt
Operating Cash Flow/Sales
Free Cash Flow Yield

Metric
Cash & Equivalents
Accounts Receivable
Inventory
Goodwill
Debt to Capitalization
Debt to Assets
Current Ratio
Quick Ratio

Metric
Rule of 40 (LTM)
Rule of 40 (NTM)
Stock Comp to Revenue
R&D to Revenue
SG&A to Revenue